Search

Search Constraints

You searched for: Author/Creator Gane, Ed

Search Results

1. Aiming for the elimination of viral hepatitis in Australia, New Zealand, and the Pacific Islands and Territories: Where are we now and barriers to meeting World Health Organization targets by 2030. Issue 1 (27th September 2018)

2. ALT flares during nucleotide analogue therapy are associated with HBsAg loss in genotype A HBeAg‐positive chronic hepatitis B. (6th March 2018)

3. Analysis of Hepatitis B Virus Haplotype Diversity Detects Striking Sequence Conservation Across Genotypes and Chronic Disease Phase. Issue 5 (29th April 2021)

5. Deep sequencing shows that HBV basal core promoter and precore variants reduce the likelihood of HBsAg loss following tenofovir disoproxil fumarate therapy in HBeAg-positive chronic hepatitis B. Issue 11 (17th August 2016)

6. Excellent Contemporary Graft Survival for Adult Liver Retransplantation: An Australian and New Zealand Registry Analysis From 1986 to 2017. Issue 8 (August 2019)

7. Faldaprevir (Bi 201335), Deleobuvir (Bi 207127) and Ribavirin Oral Therapy for Treatment-Naive HCV Genotype 1: Sound-C1 Final Results. Issue 8 (November 2013)

8. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. (March 2017)

9. HBV variants are common in the 'immune‐tolerant' phase of chronic hepatitis B. Issue 10 (17th June 2020)

10. Hepatitis B virus haplotype number at baseline is a predictive marker of functional cure during antiviral therapy for patients with genotypes A and D HBeAg‐positive chronic hepatitis B. Issue 5 (25th November 2022)